MIPS AB v Bauer Hockey Ltd 2018 FC 485 Gagné J
2,798,542 [MIPS Patent]
2,784,316 / 2,821,540 / 2,838,103 / 2,847,669 [Bauer Patents]
MIPS v Bauer concerns an
invention near and dear to me, namely sports helmets designed to
absorb rotational energy in order to minimize brain injury. (I do a lot
of cycling, and all of my
current helmets are equipped with MIPS technology.) Both Bauer and MIPS
had developed and
patented technology addressed at this problem. In this litigation, MIPS
alleged that it was a co-inventor of the Bauer technology; that the
Bauer products infringed the MIPS patent, and that the
Bauer patents were invalid. In response, Bauer attacked the validity of
the MIPS patent. The
decision, that the MIPS employees were not co-inventors of the Bauer technology, the MIPS patents were valid but not infringed, and that the narrower claims of the Bauer patents were valid, turned on the facts and claim construction.
MIPS was an early leader in this technology, which is at the core of MIPS’ business. MIPS was
founded in 2001 [15], and a patent for its first generation technology (MIPS I) was granted in
Sweden in 2002. MIPS I used a sliding facilitator apparatus to allow rotational movement
between the hard outer shell of the helmet and the inner energy-absorbing layer [13]. Its first
product using this technology, an equestrian helmet, was launched in 2007 [16]. MIPS II
technology was developed starting in 2009 [19], to address in-mold helmets, in which the inner energy
absorbing layer is fused directly to the outer shell, making it impossible to place a sliding
facilitator between the two. MIPS II technology uses an “attachment device” (3) as an interface
between the wearer’s head and the inner energy absorbing layer, allowing relative rotation
between the head and the inner layer.
Concussions are an increasing concern in hockey, and around the same time as MIPS was
developing MIPS II, Bauer was also developing a technology to address rotational impact,
specifically in hockey helmets, known as RE_AKT, using a SUSPEND-TECH floating liner.
Rotational impact is a relatively new concern in helmet design, and older testing equipment had
been made to test only linear impact. The inventorship dispute arose because part-way through its
development cycle, Bauer lost its academic partner responsible for testing, and Bauer, which had
become aware of the MIPS I helmet, approached MIPS with the aim, as Gagné J held, of having
MIPS test the Bauer designs. Gagné J’s decision recounts the details of the collaboration, but at
the end of the day, she held that the MIPS team were not co-inventors of the Bauer product. The
legal principle is that a party who tests an invention does not thereby become a co-inventor [93],
and in this case Bauer employees had wholly conceived of the inventive concept, which had only
been tested by MIPS [94], [100]. She noted that a series of events and coincidences (such as the
fact that the inner liner on both products happened to be made of yellow material) had
contributed to MIPS’ misperception of the facts [91].
On the issue of infringement, the MIPS products use an attachment device which is fixed
securely to the head, with elastic fixation members between the attachment device and the inner
energy absorbing layer. The attachment device and inner layer slide freely against one another,
and energy absorption is achieved by deformation of the fixation members. The Bauer helmets,
in contrast, have a floating liner, which is not securely attached to the head, and there are no
fixation members as such, but rather energy absorption is provided by friction between the liner
and the inner layer [184]. As Gagné J noted, to determine infringement, the defendant’s product
is compared with the patent, not with the plaintiff’s product, even if that product embodies the
invention. She held that using friction as a mechanism for absorbing rotational energy did fall
within the broadest claims of the MIPS patent [163]. However, she also held that the claimed
attachment device had to be coupled to the head, both before and during impact, and Bauer’s
SUSPEND-TECH floating liner did not operate in that manner [192]. In effect, MIPS had not
invented the concept of permitting rotation decoupling between the head and the helmet, but only
one way of achieving that decoupling, and Bauer had independently developed another method.
Because the attachment device was a crucial element of the claims, the Bauer products did not
infringe [192], [197]. (MIPS also lost on other independent points, so the finding of no
infringement did not rest on this issue alone [219].)
Bauer’s attack on the MIPS patent on the basis of anticipation and obviousness failed in large
part because MIPS got caught in an infringement / validity squeeze [231], [243]. Because the
court construed the “attachment device” more narrowly than MIPS’ experts, the validity attacks
failed but so did infringement claim. A broader interpretation of the element would have led to a
finding of invalidity [244]. (An overbreadth attack also failed on the facts [256].)
MIPS attacked the Bauer patents as being obvious in light of the MIPS II technology, which was
on sale before the Bauer patent application was filed [257]. The broadest Bauer claim was held to
be invalid for obviousness, on the basis that it would have been obvious to a skilled person to put
a MIPS attachment device inside a hockey helmet, and that would fall within the claims [286],
[287]. However, the narrow claims, addressed to Bauer’s specific implementation, were upheld
[294].
Wednesday, May 23, 2018
Thursday, May 17, 2018
Formal Protective Orders Largely Unnecessary in Light of the Strength of the Implied Undertaking Rule
Seedlings Life Science Ventures LLC v Pfizer Canada Inc 2018 FC 443 Tabib J
While I do not normally blog on procedural decisions, Tabib J’s opinion in Seedlings Life Science v Pfizer is an important decision on an important point, namely the exchange of commercially sensitive information in litigation.
In her decision in Live Face on Web, LLC v Soldan Fence and Metals (2009) Ltd, 2017 FC 858 Tabib J held that, given the existence of the implied undertaking rule, the Court ought no longer to routinely issue consent protective orders [4]. In this case, Pfizer nonetheless sought a formal protective order. Pfizer did not attempt to distinguish Live Face on Web, but in effect asked Tabib J to overrule her own recent decision [6]. Unsuprisingly, Tabib J refused to do so, and consequently she refused to grant the order sought. But Pfizer nonetheless largely achieved its purpose. Pfizer’s concern was that notwithstanding Live Face on Web, there remains such uncertainty as to the scope, application and enforceability of the implied undertaking rule, that the clarity and certainty provided by an express protective order is necessary [37]. Tabib J acknowledged the merit of Pfizer’s “thoughtful and helpful” submissions, which “highlighted the specific areas where intellectual property practitioners may have had concerns as to the scope and certainty of application of the implied undertaking rule” [66]. Rather than issuing a protective order for clarification, Tabib J clarified the law itself.
Tabib J reviewed the history and meaning of a variety of mechanisms which can be used to protect sensitive information. These include the implied undertaking rule, “pursuant to which a party to whom documents or information are transmitted in the course of pre-trial discovery is taken to have given an undertaking to the Court that he or she will not disclose or use them for any purpose other than the litigation in which they are produced. Any collateral or ulterior use constitutes a contempt of court” [3]. Tabib J explained the distinction between a protective order, relating to information that the parties will exchange between themselves in the pre-trial phase of an action, and a confidentiality order, which allows information which would be filed with the court, and so would otherwise be available to third parties, to be filed under seal. In addition, she noted that private agreements between the parties can also be used to supplement these other mechanisms.
The gist of Tabib J’s decision is that generally, the implied undertaking rule, supplemented by a private agreement between the parties, will provide adequate protection, so routine protective orders are no longer useful or necessary, and absent special circumstances they should be avoided as wasteful of the Court’s time and resources [67], [73], [74].
As to the scope and application of the implied undertaking rule, Tabib J emphasized that the sanctions for breach of the implied undertaking rule are every bit as clear and immediate as for breach of a formal protective order [60]. Further, she reiterated her holding in Live Face on Web, to the effect that [34]
(See also [75].) This is very important to her broader conclusion that protective orders are generally not needed, as she held that, given that an express agreement between the parties is enforceable by the Court, many of the specific concerns raised by Pfizer could be addressed in that manner rather than by a protective order. For example, limits on the number or categories of people who can access designated information can be addressed by supplementary undertakings.
Tabib J further clarified that the implied undertaking rule binds third parties, such as experts, consultants and service providers:
She further held that the law is clear that:
She acknowledged that it may be difficult to enforce the implied undertaking rule on persons outside the Court’s jurisdiction, but she noted that that difficulty stems from the fact that it may be difficult to enforce a contempt judgment in a foreign jurisdiction. But that difficulty is not addressed by granting a formal protective order, which is also ultimately enforceable through contempt [50]. She suggested that consequently “a party may be more likely to obtain effective relief against breach of protective measures by asking the foreign court to recognize and enforce the underlying obligation” [50].
She also held that “the case law has clearly recognized that the implied undertaking does not prevent use of information that was obtained from other [non-confidential] sources [59].
She did leave open the question of whether protective orders should be issued in proceedings other than actions, in which the implied undertaking rule might not be applicable [58].
In concluding, Tabib J suggested that some misconceptions about the nature of the implied undertaking rule may stem from the “climate of uncertainty” as to the nature of the rule up to the 1990s, before clarifying jurisprudence had developed, and as a result of familiarity with US practice. Tabib J emphasized the distinction from US practice, “where the concept of the implied undertaking does not exist and where, as a result, protective orders are routinely issued” [67]. She emphasized the need for lawyers dealing with clients who are familiar with US practice to educate those clients “of the existence of the implied undertaking rule, of the restrictions on the use of this information and of the penalties they may face if the restrictions are breached, even in the absence of a formal order or agreement” [69].
While I do not normally blog on procedural decisions, Tabib J’s opinion in Seedlings Life Science v Pfizer is an important decision on an important point, namely the exchange of commercially sensitive information in litigation.
In her decision in Live Face on Web, LLC v Soldan Fence and Metals (2009) Ltd, 2017 FC 858 Tabib J held that, given the existence of the implied undertaking rule, the Court ought no longer to routinely issue consent protective orders [4]. In this case, Pfizer nonetheless sought a formal protective order. Pfizer did not attempt to distinguish Live Face on Web, but in effect asked Tabib J to overrule her own recent decision [6]. Unsuprisingly, Tabib J refused to do so, and consequently she refused to grant the order sought. But Pfizer nonetheless largely achieved its purpose. Pfizer’s concern was that notwithstanding Live Face on Web, there remains such uncertainty as to the scope, application and enforceability of the implied undertaking rule, that the clarity and certainty provided by an express protective order is necessary [37]. Tabib J acknowledged the merit of Pfizer’s “thoughtful and helpful” submissions, which “highlighted the specific areas where intellectual property practitioners may have had concerns as to the scope and certainty of application of the implied undertaking rule” [66]. Rather than issuing a protective order for clarification, Tabib J clarified the law itself.
Tabib J reviewed the history and meaning of a variety of mechanisms which can be used to protect sensitive information. These include the implied undertaking rule, “pursuant to which a party to whom documents or information are transmitted in the course of pre-trial discovery is taken to have given an undertaking to the Court that he or she will not disclose or use them for any purpose other than the litigation in which they are produced. Any collateral or ulterior use constitutes a contempt of court” [3]. Tabib J explained the distinction between a protective order, relating to information that the parties will exchange between themselves in the pre-trial phase of an action, and a confidentiality order, which allows information which would be filed with the court, and so would otherwise be available to third parties, to be filed under seal. In addition, she noted that private agreements between the parties can also be used to supplement these other mechanisms.
The gist of Tabib J’s decision is that generally, the implied undertaking rule, supplemented by a private agreement between the parties, will provide adequate protection, so routine protective orders are no longer useful or necessary, and absent special circumstances they should be avoided as wasteful of the Court’s time and resources [67], [73], [74].
As to the scope and application of the implied undertaking rule, Tabib J emphasized that the sanctions for breach of the implied undertaking rule are every bit as clear and immediate as for breach of a formal protective order [60]. Further, she reiterated her holding in Live Face on Web, to the effect that [34]
an express agreement between the parties, whereby they recognize that such measures
constitute undertakings given to the Court as additional protection to their privacy interest
for the purposes of the litigation, is amenable to enforcement by this Court, including by
way of contempt proceedings, without the need to be first acknowledged by the Court or
enshrined in an order:
(See also [75].) This is very important to her broader conclusion that protective orders are generally not needed, as she held that, given that an express agreement between the parties is enforceable by the Court, many of the specific concerns raised by Pfizer could be addressed in that manner rather than by a protective order. For example, limits on the number or categories of people who can access designated information can be addressed by supplementary undertakings.
Tabib J further clarified that the implied undertaking rule binds third parties, such as experts, consultants and service providers:
[40] Discovery information is primarily disclosed to and controlled by the parties and
their solicitors. Pursuant to the implied undertaking, they have no right to disclose that
information to anyone, including third party experts, consultants or service providers,
unless it is necessary for the conduct of the litigation. In that role, these third parties act as
agents or sub-contractors for the parties. It would be unthinkable that these agents would
not be bound by the same obligation as their principals. To entertain the contrary would
be to accept that the important protection intended to be afforded by the implied
undertaking could be defeated and rendered nugatory simply by allowing a party to act
through an agent.
She further held that the law is clear that:
[49] A person who is aware of the application of the implied undertaking rule or of any
order issued by this Court, whether or not they have given an express undertaking to
attorn to the Court’s jurisdiction, is under a duty to this Court not to interfere with justice
by acting in such a way as to breach the intent and purpose of the rule or order
She acknowledged that it may be difficult to enforce the implied undertaking rule on persons outside the Court’s jurisdiction, but she noted that that difficulty stems from the fact that it may be difficult to enforce a contempt judgment in a foreign jurisdiction. But that difficulty is not addressed by granting a formal protective order, which is also ultimately enforceable through contempt [50]. She suggested that consequently “a party may be more likely to obtain effective relief against breach of protective measures by asking the foreign court to recognize and enforce the underlying obligation” [50].
She also held that “the case law has clearly recognized that the implied undertaking does not prevent use of information that was obtained from other [non-confidential] sources [59].
She did leave open the question of whether protective orders should be issued in proceedings other than actions, in which the implied undertaking rule might not be applicable [58].
In concluding, Tabib J suggested that some misconceptions about the nature of the implied undertaking rule may stem from the “climate of uncertainty” as to the nature of the rule up to the 1990s, before clarifying jurisprudence had developed, and as a result of familiarity with US practice. Tabib J emphasized the distinction from US practice, “where the concept of the implied undertaking does not exist and where, as a result, protective orders are routinely issued” [67]. She emphasized the need for lawyers dealing with clients who are familiar with US practice to educate those clients “of the existence of the implied undertaking rule, of the restrictions on the use of this information and of the penalties they may face if the restrictions are breached, even in the absence of a formal order or agreement” [69].
Sunday, May 13, 2018
No new cases
No new substantive patent cases were released last week.
Subscribe to:
Posts (Atom)